

## Drug Status Report


**Drug:** O-1602

**Drug Name Status:** O-1602 is the common name


**Chemical Name:**

5-Methyl-4-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-1,3-benzenediol

**Chemical structure:**



O-1602



Cannabidiol

**Molecular Formula:** C<sub>17</sub>H<sub>22</sub>O<sub>2</sub>

**Pharmacological class / Application:** potential vasodilator

**International status:**

US: O-1602 is not currently listed explicitly on the schedules to the US Controlled Substances Act and is not mentioned on the DEA website.

United Nations: The substances are not listed on the Yellow List - List of Narcotic Drugs under International Control nor the Green List - List of Psychotropic Substances under International Control.

Canadian Status: O-1602 is structurally related to cannabidiol (above). Note that the alkyl side chains and one OH group are transposed in O-1602 and cannabidiol. O-1602 is offered for sale by two companies - Tocris<sup>1</sup> and Cayman<sup>2</sup>. Both these sites give references to different research publications implying that O-1602 is a cannabinoid agonist. Neither paper cited mentions O-1602. Rather these two papers discuss “abnormal cannabidiol” the pentyl analogue of O-1602, There is no information currently in the literature to support the claim that O-1602 is active on cannabinoid receptors. Using the CAS# for O-1602, there are no scientific publications in PubMed on O-1602.

---

<sup>1</sup> <http://www.tocris.com/dispprod.php?ItemId=5287>

<sup>2</sup> <http://www.caymanchem.com/app/template/Product.vm/catalog/10006803/a/z>

Recommendation: O-1602 is not included in the schedules to the CDSA and is not a controlled substance.

August 8, 2007

(Revised August 14, 2008)